Novel role of thromboxane receptors β isoform in bladder cancer pathogenesis

Cancer Research

Volumn 68, Issue 11, 2008, Pages 4097-4104

  Moussa, Omar ^a,b   Ashton, Anthony W ^c,e   Fraig, Mostafa ^a,b,f   Garrett Mayer, Elizabeth ^b   Ghoneim, Mohamed A ^d   Halushka, Perry V ^a   Watson, Dennis K ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MANSOURA UNIVERSITY   (Egypt)

^e UNIVERSITY OF SYDNEY   (Australia)

^f DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; BETA ARRESTIN 2; CISPLATIN; FOCAL ADHESION KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR ALPHA; THROMBOXANE RECEPTOR BETA; UNCLASSIFIED DRUG; VAPIPROST; ISOPROTEIN; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UROTHELIUM; ANIMAL; BLADDER TUMOR; CANCER INVASION; CELL DIVISION; CELL MOTION; DRUG ANTAGONISM; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DNA PRIMERS; HUMANS; MICE; NEOPLASM INVASIVENESS; PROTEIN ISOFORMS; RECEPTORS, THROMBOXANE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 49249138363     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6560     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Moussa O, Yordy JS, Abol-Enein, et al. Prognostic and functional significance of thromboxane synthase gene over-expression in invasive bladder cancer. Cancer Res 2005;65:11581-7.
3. Needleman PM, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science 1976;193:163-5.
4. Morinelli TA, Oatis JE, Jr., Okwu AK, et al. Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther 1989;251:557-62.
5. Halushka PV, Pawate S, Martin ML. Thromboxane A2 and Other Eicosanoids. In: Von Bruchhusen F, Walter U, editors. Handbook of Experimental Pharmacology, Platelets and Their Factors, Vol. 126. Berlin (Germany): Springer-Verlag; 1997. p. 459-82.
6. Halushka PV. Thromboxane A(2) receptors: where have you gone? Prostaglandins Other Lipid Mediat 2000;60:175-89.
7. Hirata M, Hayashi Y, Ushikubi F, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991;349:617-20.
8. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 1994;269:19256-61.
9. Miggin SM, Kinsella BT. Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) α and β isoforms. Biochim Biophys Acta 1998;1425:543-59.
10. Becker KP, Garnovskaya M, Gettys T, Halushka PV. Coupling of thromboxane A2 receptor isoforms to Gα13: effects on ligand binding and signalling. Biochim Biophys Acta 1999;1450:288-96.
11. Shenker A, Goldsmith P, Unson CG, Spiegel AM. The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. J Biol Chem 1991;266:9309-13.
12. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994;94:1662-7.
13. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996;97:949-56.
14. Nagata T, Uehara Y, Numabe A, et al. Regulatory effect of thromboxane A2 on proliferation of vascular smooth muscle cells from rats. Am J Physiol 1992;263:H1331-8.
15. Miggin SM, Kinsella T. Regulation of extracellular signal-regulated kinase cascades by α- and β-isoforms of the human thromboxane A2 receptor. Mol Pharm 2002;61:817-31.
16. Gao Y, Tang S, Zhou S, Ware JA. The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther 2001;296:426-33.
17. Muscheck M, Abol-Enein H, Chew K, et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 2000;21:1721-6.
18. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003;63:4626-31.
19. Kelley-Hickie LP, Kinsella BT. Homologous desensitization of signalling by the β (β) isoform of the human thromboxane A2 receptor. Biochim Biophys Acta 2006;1761:1114-31.
20. Kelly P, Stemmle LN, Madden JF, Fields TA, Daaka Y, Casey PJ. A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J Biol Chem 2006;281:26483-90.
21. Kelly P, Moeller BJ, Juneja J, et al. The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci U S A 2006;103:8173-8.
22. Casey MB, Zhang S, Jin L, Kajita S, Lloyd RV. Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions. Endocr Pathol 2004;15:107-16.
23. Nie D, Che M, Zacharek A, et al. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 2004;164:429-39.
24. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas. Endocr Pathol 2004;15:17-27.
25. Yoshimoto A, Kasahara K, Kawashima A, Fujimura M, Nakao S. Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncol Rep 2005;13:1049-57.
26. Theriault C, Rochdi MD, Parent JL. Role of the Rab11-associated intracellular pool of receptors formed by constitutive endocytosis of the β isoform of the thromboxane A2 receptor (TP β). Biochemistry 2004;43:5600-7.
27. Rochdi MD, Laroche G, Dupre E, et al. Nm23-2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. J Biol Chem 2004;279:18981-9.
28. Parent JL, Labrecque P, Orsini MJ, Benovic JL. Internalization of the TXA2 receptor α and β isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 1999;274:8941-8.
29. Parent JL, Labrecque P, Driss Rochdi M, Benovic JL. Role of the differentially spliced carboxyl terminus in thromboxane A2 receptor trafficking: identification of a distinct motif for tonic internalization. J Biol Chem 2001;276:7079-85.
30. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 2006;103:1492-7.
31. Bokemeyer C, Hartmann JT, Kuczyk MA, et al. Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol 1998;16:155-62.
32. Sternberg CN, Calabro F. Chemotherapy and management of bladder tumours. BJU Int 2000;85:599-610.
33. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 1985;249:F490-6.
34. Jariyawat S, Takeda M, Kobayashi M, Endou H. Thromboxane A2 mediates cisplatin-induced apoptosis of renal tubule cells. Biochem Mol Biol Int 1997;42:113-21.
35. Blochl-Daum B, Pehamberger H, Kurz C, et al. Effects of cisplatin on urinary thromboxane B2 excretion. Clin Pharmacol Ther 1995;58:418-24.
36. Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992;41:1483-93.
37. Fitzgerald GA, Healy C, Daugherty J. Thromboxane A2 biosynthesis in human disease. Fed Proc 1987;46:154-8.
38. Kasahara K, Fujimura M, Bando T, Shibata K, Shirasaki H, Matsuda T. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines. Br J Cancer 1996;74:1553-8.
39. Fujimura M, Kasahara K, Shirasaki H, et al. Upregulation of ICH-1L protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines. J Cancer Res Clin Oncol 1999;125:389-94.
40. Thomas M, Lumley P. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects. Circulation 1990;81:I53-8; discussion I9-60.
41. Finnerty JP, Twentyman OP, Harris A, Palmer JB, Holgate ST. Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma. Thorax 1991;46:190-2.
42. Humphrey PP, Hallet P, Hornby EJ, Wallis CJ, Collington EW, Lumley P. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Circulation 1990;81:I42-52; discussion I9-60.